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Abstract
Background: Dynamic Mechanical Allodynia (DMA) is a typical
symptom of neuropathic pain (NP). In a recent study, the capsaicin 8%
patch was noninferior to pregabalin in overall peripheral NP relief. In
this study, we report the comparison of the two treatments in relieving
DMA.
Methods: In a randomized, open-label, head-to-head, 8-week study,
488 patients with peripheral NP were treated with the capsaicin 8%
patch (one application) or an optimized dose of pregabalin. Assessments
included the area and intensity of DMA, and the number of patients
achieving complete resolution of DMA.
Results: At baseline, 253 patients in the capsaicin 8% patch group and
235 patients in the pregabalin group had DMA. From baseline to end of
study, the change in DMA intensity was significantly in favour of the
capsaicin 8% patch versus pregabalin [0.63 (95% CI: 1.04, 0.23;
p = 0.002)]. Similarly, the capsaicin 8% patch was superior to
pregabalin in reducing the area of DMA [39.5 cm2 (95% CI: 69.1,
10.0; p = 0.009)] from baseline to end of study. Overall, a greater
proportion of patients had a complete resolution of allodynia with
capsaicin 8% patch treatment compared with pregabalin treatment
(24.1% vs. 12.3%; p = 0.001) at end of study.
Conclusion: Capsaicin 8% treatment was superior to pregabalin in
reducing the intensity and area of DMA, and in the number of patients
with complete resolution of DMA.
Significance: The superiority of a topical treatment over pregabalin in
relieving DMA supports the view that both peripheral and central
sensitization can mediate allodynia.
1. Introduction
Allodynia, a common clinical manifestation of
peripheral neuropathic pain (NP), arises due to a
stimulus that does not normally provoke pain and
involves a change in the quality of sensation (IASP,
2014; Jensen and Finnerup, 2014). The incidence of
allodynia in NP disorders varies, with prevalence
estimates of 31%, 75% and 79% in painful polyneu-
ropathy, postherpetic neuralgia (PHN) and postinjury
NP, respectively (Maier et al., 2010). Dynamic
mechanical allodynia (DMA) is pain evoked by light
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brushing or stroking of the skin (Truini et al., 2013b;
Jensen and Finnerup, 2014) and may be generated
by several different mechanisms.
Compelling evidence supports the widely held
view that DMA represents a form of secondary
hyperalgesia due to altered processing of low-thresh-
old large diameter A-beta fibres in the central ner-
vous system (CNS), commonly referred to as central
(or indirect) sensitization (Hansson, 2014; Jensen and
Finnerup, 2014). Microneurographic studies have
shown that blocking of A-receptors by compression
can also block DMA both in animal and in human
models (Campbell et al., 1988; Torebjork et al.,
1992; Ochoa and Yarnitsky, 1993). The temporal
dynamics of DMA behaviour in animal models of
nerve ligature are compatible with conduction in
myelinated fibres, in the absence of C-activation (Liu
et al., 2000; Sun et al., 2005). Previously proposed
mechanisms of DMA, such as aberrant reinnervation
by collaterals of A-beta primary afferents on deaffer-
ented second-order nociceptive neurons (Koltzen-
burg et al., 1992, 1994; Ochoa and Yarnitsky, 1993;
Fields et al., 1998; Landerholm and Hansson, 2011),
are nowadays thought to occur less frequently (Cer-
vero and Laird, 1996). It is generally accepted that
central sensitization is maintained in part by contin-
uous input from nociceptors (Woolf, 2009; Baron
et al., 2013). Others, who favour a peripheral (or di-
rect) mechanism, believe that low-threshold,
mechano-sensitive C fibres (C tactile fibres), may
independently contribute to mechanical allodynia.
Moreover, microneurography (Ochoa et al., 2005;
Serra et al., 2011), laser-evoked potential (Truini
et al., 2013a), skin biopsy (Truini et al., 2014) and
pharmacological studies (Haroutounian et al., 2014),
consistently provide evidence suggesting that periph-
eral sensitization of mechanothermal nociceptors,
innervated by A-delta and C fibres (mechano-heat
units), induces lowering of the mechanical threshold
to a level that allows direct excitation by innocuous
stimuli, thus offering an alternative target for topical
capsaicin.
We postulated that application of high-concentra-
tion topical capsaicin, acting on C fibres that supply
the pain area, would lead to a reduction in periph-
eral and central sensitization and subsequent attenu-
ation of DMA. Capsaicin is a potent, highly selective
vanilloid receptor subtype 1 (TRPV1) agonist that
causes depolarization of the neurons, inducing a
short-lived warming sensation, followed by complete
defunctionalization (Anand and Bley, 2011). The
efficacy and tolerability of the capsaicin 8% patch
has been confirmed in PHN, painful human
immunodeficiency virus (HIV)-associated neu-
ropathies (Backonja et al., 2008; Simpson et al.,
2008; Irving et al., 2011; Brown et al., 2013), and
more recently in painful diabetic peripheral neuropa-
thy (Simpson et al., 2016; Vinik et al., 2016).
Clinical trials specifically investigating the treat-
ment of evoked pain are sparse and currently there
are no defined standard of care treatments for DMA
(Jensen and Finnerup, 2014). Pregabalin is a well-
established and widely used treatment for NP (Attal
et al., 2010), which has been shown to reduce allo-
dynia in experimental studies (Tuchman et al.,
2010), and was significantly better than placebo in
alleviating DMA in patients with PHN (Stacey et al.,
2008). Whilst these studies have demonstrated the
clinical benefit of pregabalin in allodynia, including
a correlation between changes in the intensity of
DMA and overall pain (Stacey et al., 2008), the rela-
tionship between changes in the area of allodynia
and a clinical response remains to be explored.
In the recently completed ELEVATE study, the
capsaicin 8% patch demonstrated noninferior pain
relief versus an optimized dose of pregabalin over
8 weeks (primary endpoint), with a faster onset of
action, fewer systemic side effects and greater patient
satisfaction with treatment (Haanp€a€a et al., 2016).
Here, we report results regarding the intensity and
area of DMA, which formed secondary outcome
measures, in the same study population.
2. Methods
2.1 Study design and participants
The ELEVATE (NCT01713426) study was a Phase IV,
randomized, open-label, head-to-head, 8-week, non-
inferiority study, conducted in Europe between July
2012 and September 2013 (Haanp€a€a et al., 2016).
Eligible patients were: aged 18–80 years; had a docu-
mented diagnosis of probable or definite peripheral
NP due to PHN (Treede et al., 2008), peripheral
nerve injury (PNI) or nondiabetic painful polyneu-
ropathy; had an average Numeric Pain Rating Scale
(NPRS) score ≥4 at screening (over at least four con-
secutive days); were na€ıve to treatment with the
capsaicin 8% patch and were na€ıve to, or had not
received adequate treatment with, pregabalin and
gabapentin; and provided written consent. Exclusion
criteria included the following: significant ongoing or
recurrent pain of an aetiology other than PHN, PNI
or nondiabetic painful polyneuropathy; Complex
Regional Pain Syndrome; NP related to previously
administered radiotherapy, diabetes mellitus or HIV-
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associated neuropathy; or NP areas located only on
the face, above the hairline of the scalp, and/or in
proximity to mucous membranes. Full inclusion and
exclusion criteria and patient characteristics and
demographics are reported elsewhere (Haanp€a€a
et al., 2016).
2.2 Treatment and assessments
Patients were randomized to receive the capsaicin
8% patch (a single application, 640 lg/cm2, of up to
four patches per application) or an optimized dose of
pregabalin (150–600 mg/day administered in two or
three doses) (Haanp€a€a et al., 2016). The endpoints
for DMA analysis were the change in the intensity
and the area of allodynia from baseline to Week 8.
Allodynia was analyzed in all randomized patients
who initiated study treatment. The analyses of
changes in allodynia were based on patients with
allodynia at baseline, which was defined as patients
with pain intensity >0 (NPRS score) and a sensitive
area of allodynia >0 cm2.
The area of DMA was identified by patients, and
mapped by the physician, at screening, baseline and
end of study (EoS) in all patients. Mapping was per-
formed using a brush to gently stroke the skin from
outside the area indicated by the patient towards the
centre, from six to eight directions (from above,
below, left, right, etc.). A fixed velocity was not
instructed for the brush strokes, as validated infor-
mation for a suitable technique has not been pub-
lished. Short strokes were used, based on clinical
experience among the investigators, performed in a
meticulous and careful manner with some seconds
allowed for the patient to respond after each sweep.
The exact location where the stroke became painful
was marked on the skin. The points were joined
with a dashed line to outline the perimeter of the
area, which was traced onto a sheet of acetate. The
acetate was then placed on graph paper and the
squares (1 cm2) were counted to calculate the area.
To obtain the pain intensity score for DMA, the
examiner applied three strokes to the centre of the
allodynic area, maintaining the same direction and
speed (about 5 cm per second) (Samuelsson et al.,
2005) and purporting to maintain a constant force
against the skin. A predetermined length of the
stroke could not be provided, as patients with allo-
dynic areas of varying sizes were entered into the
study and, based on previous clinical observations
of capsaicin 8% patch treatment, the possibility
that the allodynic areas could shrink had to be
considered. After the third stroke, the patient was
asked to rate the intensity of the pain, evoked by
the brush and independent of the ongoing back-
ground pain, using the 11-point NPRS scale rang-
ing from 0 (no pain) to 10 (worst imaginable
pain).
2.3 Statistical methodology
The mean change per treatment group and differ-
ence between them were estimated using an analysis
of covariance model adjusted for gender, baseline
value (area/intensity of allodynia) and individual
country (post hoc analysis). Least square (LS) means
per treatment group and difference in LS means with
associated 95% confidence interval (CI) and p-value
were provided. Baseline observation carried forward
was applied in cases of missing data.
3. Results
3.1 Allodynia prior to treatment
Patient characteristics for DMA at screening and
baseline were similar. At screening, patients rando-
mized to treatment with the capsaicin 8% patch
(n = 240) had a mean (SD; standard deviation)
intensity and area of DMA of 6.59 (1.82) and 223.0
(247.0) cm2, respectively. The corresponding figures
for patients treated with pregabalin (n = 225) were
6.70 (1.63) and 237.5 (283.1) cm2, respectively. At
baseline, patients randomized to the capsaicin 8%
patch (n = 253) had a mean (SD) intensity and area
of DMA of 6.60 (1.66) and 228.3 (252.8) cm2, while
the corresponding figures for pregabalin (n = 235)
were 6.71 (1.58) and 234.0 (272.5), respectively. No
significant differences were observed between the
two treatment groups either at screening or baseline,
or between screening and baseline in the intensity
or area of DMA. The number of patients with mild
allodynia (NPRS score <4) was the same in each
treatment group (n = 8).
3.2 Change in intensity of allodynia
The LS mean [standard error (SE)] change in inten-
sity of DMA, from baseline to Week 8/EoS, was
2.98 (0.20) in the capsaicin 8% patch group and
2.35 (0.21) in the pregabalin group, significantly in
favour of the capsaicin 8% patch [difference in LS
means: 0.63 (95% CI: 1.04, 0.23; p = 0.002)]
(Fig. 1).
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3.3 Change in area of allodynia
The LS mean (SE) change in area of DMA, from
baseline to Week 8/EoS, was 72.6 cm2 (14.2) in
the capsaicin 8% patch group and 33.1 cm2 (15.5)
in the pregabalin group [difference in LS
means: 39.5 cm2 (95% CI: 69.1, 10.0; p =
0.009)] (Fig. 2).
Significantly more patients had complete resolu-
tion of allodynia in the capsaicin 8% patch group
compared with patients in the pregabalin group at
Week 8/EoS (24.1% vs. 12.3%; p = 0.001)
(Table 1).
3.4 Tolerability
In the ELEVATE study, fewer systemic side effects
were observed with the capsaicin 8% patch com-
pared with pregabalin (Haanp€a€a et al., 2016). The
majority of the treatment-emergent adverse events
with the capsaicin 8% patch were mild or moderate,
and the most frequent were application site pain,
application erythema and a burning at the site of
application. Treatment-emergent adverse events
leading to permanent treatment discontinuation
were only reported for pregabalin (n = 24; 8.5%).
4. Discussion
Our study confirms that DMA, defined as pain
evoked by brushing, is common in patients with
peripheral NP, as previously reported (Attal et al.,
2008; Baron, 2009; Maier et al., 2010; Jensen and
Finnerup, 2014). In this head-to-head comparison
study, significantly greater reductions in the inten-
sity and area of DMA were seen after a single appli-
cation of capsaicin 8% patch compared with
optimized dose pregabalin over 8 weeks. Further-
more, the superiority in efficacy was not restricted to
patients with mild allodynia (NPRS score <4), as
these patients represented a minority (16 of 488) of
the study population compared with those who had
moderate-to-severe allodynia (NPRS score ≥4). Fur-
thermore, capsaicin 8% patch was superior to prega-
balin in the proportion of patients whose allodynia
was completely controlled at EoS (Table 1). This
improvement is of clinical importance when consid-
ering the functional disability that can be caused by
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Figure 1 Mean change in intensity of dynamic mechanical allodynia
from baseline to Week 8/EoS (BOCF). BOCF, baseline observation car-
ried forward; EoS, end of study; LS, least squares; n, number of all
patients with allodynia at baseline; NPRS, Numeric Pain Rating Scale.
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Figure 2 Mean change in area of dynamic mechanical allodynia from
baseline to Week 8/EoS (BOCF). BOCF, baseline observation carried
forward; EoS, end of study; LS, least squares; n, number of all patients
with allodynia at baseline.
Table 1 Proportion of patients in each treatment group who experi-
enced complete disappearance of dynamic mechanical allodynia at
Week 8 (end of study).
Complete
disappearance
Capsaicin 8% patch
(n = 253)
Pregabalin
(n = 235) Significanceb
Yesa, n (%) 61 (24.1) 29 (12.3)
p = 0.001
No, n (%) 192 (75.9) 206 (87.7)
n, number of all patients with allodynia at baseline.
aDefined as postbrush Numeric Pain Rating Scale = 0.
bThe association between treatment and complete disappearance (chi-
square test).
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allodynia and the lack of recognized treatment
options (Svendsen et al., 2005; Jensen and Finnerup,
2014).
Topical capsaicin acts directly on TRPV1 mem-
brane receptors of nociceptors (C and A-delta) to
induce defunctionalization of the peripheral termi-
nals (Anand and Bley, 2011). C-nociceptor input
into the CNS is considered a key mechanism
whereby central sensitization of second-order neu-
rons is maintained (Baron et al., 2013). With
reduced C-nociceptor input, centrally maintained
activation of nociceptive pathways is lessened or
removed. However, it is important to note that
although the density of epidermal nerve fibres (pre-
dominantly C fibres) is usually reduced in painful
peripheral NP, it is higher in those with DMA com-
pared with those without (Truini et al., 2014). DMA
may be maintained by excessive activity in spared C-
nociceptors as suggested by a study using laser-
evoked potentials (Truini et al., 2013a).
It has also been proposed that DMA could be
mediated directly by activation of normally dormant
low-threshold C mechanoreceptors or by irritable
nociceptors, that is high-threshold mechanothermal
C-nociceptors with thresholds lowered by peripheral
sensitization to the point of responding to low-inten-
sity stimuli, such as a gentle brushing. In agreement
with this, microneurographic studies showed that
light mechanical stimulation abnormally activates C-
nociceptors in painful polyneuropathy (Kleggetveit
et al., 2012).
Although TRPV1 receptors are expressed in C-
and A-delta afferents in na€ıve animals only, it has
been suggested that non-nociceptive myelinated
fibres can be expressed following nerve injury
(Zakir et al., 2012). However, it remains to be
shown if this happens in A-beta fibres in human
subjects and if this leads to DMA. Indirect evidence
in support of this possibility comes from a study
involving a small number of patients (n = 20) with
peripheral NP treated with capsaicin 8% patch
(Mainka et al., 2016). While a significant elevation
of warm detection threshold was detected in the
affected skin area following capsaicin treatment, it
did not correlate with reported pain relief (Mainka
et al., 2016). A further potential mechanism for C
afferent dependent mechanical allodynia comes
from evidence of C- and A-beta fibre cross-excita-
tion in the dorsal root ganglia in neuropathic ani-
mals (Amir and Devor, 2000). Putatively,
defunctionalization by topical capsaicin could atten-
uate the hyperexcitable C afferents in this mecha-
nism. However, no studies have been published to
date to indicate whether this mechanism is present
in patients experiencing pain.
While the ELEVATE study demonstrated noninfe-
riority in overall pain reduction between pregabalin
and the capsaicin 8% patch, the latter was clearly
superior in relieving DMA and was associated with
fewer treatment-emergent adverse events (Haanp€a€a
et al., 2016). Pregabalin is known to be efficacious
in allodynia/hyperalgesia by modulating the calcium
inflow into presynaptic terminals of primary affer-
ents and thus reducing central sensitization (Tuch-
man et al., 2010), that is only indirectly. We propose
that capsaicin was specifically superior in relieving
allodynia because it can act both indirectly (by
reducing central sensitization) and directly (by reduc-
ing peripheral sensitization). These are the first data
to indicate a direct role for capsaicin in relieving
DMA.
We acknowledge limitations of the ELEVATE
study including challenging recruitment, open-label
design and limited study duration (Haanp€a€a et al.,
2016). More specific limitations concern the methods
for evoking and measuring DMA over three separate
sessions. To maximize accuracy and repeatability
while accommodating the demands of a multicentre
study, we adopted the common method for evoking
tactile allodynia using a hand-held light-weight
brush (Samuelsson et al., 2011). Previous studies
show that in patients with peripheral neuropathy,
the intensity of manually evoked brush allodynia is
highly repeatable in several measurements made
over a 30-day period, with intraclass correlation
coefficients ranging from 0.89 to 0.95, when the
direction, velocity and the length of the brush sweep
and the number of strokes and force exerted by the
brush on the skin are kept constant (Samuelsson
et al., 2005, 2007, 2011). This fact was emphasized
to the examiners who also received detailed instruc-
tions for applying the appropriate test technique at
investigator meetings. Patients were reminded to rate
the brush-evoked pain independently of the back-
ground pain. The method for assessing the area of
allodynia was based on the patient’s ability to reli-
ably judge the margin at which nonpainful brushing
becomes clearly painful. The identification of the
boundaries of the allodynic areas has been success-
fully used in the past for both experimentally
induced and clinical allodynia, although we are not
aware of formal validation studies (Harding et al.,
2001; Sjolund et al., 2001). In this study, allodynic
areas measured at screening and baseline were
remarkably similar. In addition, in a significant per-
centage of patients, the measurement at EoS
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indicated complete disappearance of DMA, making a
powerful argument for a genuine impact of capsaicin
8% patch on DMA.
Caution should be used in extrapolating the
results to other forms of allodynia in neuropathic
and/or non-neuropathic conditions. Future studies
should address the issue of various subclasses of allo-
dynia and hyperalgesia (Backonja et al., 2013) as
well as the time to onset of relief from allodynic
pain. Such studies should be based on a large num-
ber of known mechanisms for evoked pain (Meac-
ham et al., 2017) and be adequately powered. The
recent mechanistic study on the effects of capsaicin
8% patch that showed no impact on thermal and
punctate hyperalgesia (or, indeed DMA) was likely
underpowered (Mainka et al., 2016).
In conclusion, this study indicates that the cap-
saicin 8% patch provides stronger clinical benefits
than pregabalin in treating DMA (reduction in area,
reduction in intensity and number of patients reach-
ing complete removal of allodynia). Whereas prega-
balin can only act on central sensitization, the
superiority of the capsaicin 8% patch in DMA may
be due to capsaicin’s ability to act on both central
and peripheral sensitization.
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